Rs 2,200 drug can treat hepatitis B patient

Thursday, April 23, 2015

London (IANS): A drug for treating hepatitis B virus (HBV) could be mass-produced at a fraction of its current price — for only $36 (Rs 2,267) per person per year, versus the current US price of over $15,000 (Rs 944,775), say researchers from University of Liverpool in Britain.

Hepatitis B causes liver cancer and liver cirrhosis, both of which can be fatal. It is transmitted through blood and infected bodily fluids. There is also a risk of infected mothers passing on the Hepatitis B virus to their children.

“We have shown that the Hepatitis B drug, entecavir, could be mass produced for only $36 per person per year. Combining mass vaccination with mass treatment would lead to huge reductions in the number of people being infected with Hepatitis B, and could significantly lower the death rates from the current 686,000 per year worldwide,” said Andrew Hill, senior visiting research fellow in the University’s Department of Pharmacology.

The researchers analysed the factors which influence the cost of manufacturing of drugs for hepatitis B, including the cost of the raw materials, the amount of drug needed and the patent situation of each drug.

They found that the drug entecavir (Baraclude, Bristol Myers Squibb) has the potential to be mass produced as a generic drug at a fraction of its current price which would mean that all countries, including poorer/developing countries, could afford to use it.

Entecavir is an effective antiviral drug used in the treatment of HBV infection with few adverse side effects to patients, low levels of resistance.

The dose is only 0.5 milligrams per day, so only a fifth of a gram would need to be produced to provide a year’s supply. This is one reason why this drug is so cheap to manufacture.

Currently, entecavir is the most expensive drug for hepatitis B on the market in both developed and developing countries.

However, the expiration of its patent in February 2015 in the US and other countries means it could now be manufactured as a generic drug by other companies at a far lower cost.

The study appeared in the Journal of Virus Eradication.

Categories: Medicine, Pharmacology, RESEARCH

Tags: , , , , , ,

  More from Medicine

Safety concerns linger for generic oncology drugs in developing countries

Pharmaceutical industry-sponsored meals associated with higher prescribing rates

Researchers combine drugs to develop a new treatment for human parainfluenza virus

Common painkillers are more dangerous than we think

Stronger evidence found for link between prenatal exposure to paracetamol and the risk of developing asthma

US scientists document trajectory of Zika virus for first time

1 Comment »

Comment by drashaghe
2017-02-22 06:24:28

Thanks to Dr Ashaghe who cured me of hepatitis B, I was almost hopeless when the virus was ravaging my system, until I melt Dr Ashaghe’s testimonies online, on how he has cured so many people on the same sickness, and I contacted him, and he administered his herbal medication on me, and I was cured in weeks, in case you wants to reach him for a similar problem, you can call +2347080283038 or email

Name (required)
E-mail (required - never shown publicly)
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> in your comment.